Journal
JOURNAL OF TISSUE ENGINEERING
Volume 12, Issue -, Pages -Publisher
SAGE PUBLICATIONS INC
DOI: 10.1177/20417314211000304
Keywords
Tissue engineering; microvascular fragments; vascularization; erythropoietin; wound healing
Categories
Funding
- Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [LA 2682/7-2]
- Saarland University
Ask authors/readers for more resources
This study demonstrates that systemic low-dose erythropoietin (EPO) treatment can enhance the vascularization capacity and viability of adipose tissue-derived microvascular fragments (MVF).
Adipose tissue-derived microvascular fragments (MVF) are used as vascularization units in tissue engineering. In this study, we investigated whether the vascularization capacity of MVF can be improved by systemic low-dose erythropoietin (EPO) administration. MVF were isolated from the epididymal fat of donor mice and seeded onto collagen-glycosaminoglycan matrices, which were implanted into full-thickness skin defects within dorsal skinfold chambers of recipient mice. Both donor and recipient mice were treated daily with either EPO (500 IU/kg) or vehicle (0.9% NaCl). The implants were analyzed by stereomicroscopy, intravital fluorescence microscopy, histology, and immunohistochemistry. EPO-treated MVF contained a comparable number of proliferating Ki67(+) but less apoptotic cleaved caspase-3(+) endothelial cells when compared to vehicle-treated controls. Moreover, EPO treatment accelerated and improved the in vivo vascularization, blood vessel maturation, and epithelialization of MVF-seeded matrices. These findings indicate that systemic low-dose EPO treatment is suitable to enhance the viability and network-forming capacity of MVF.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available